Apr 20, 2021 11:42 AM (GMT+8) · EqualOcean
On April 20, nuocheng Jianhua, a biomedical high-tech company, announced today that its new multi-target receptor tyrosine kinase (RTK) inhibitor icp-033 new drug research (ind) application has been accepted by the State Drug Administration (nmpa). Icp-033 can inhibit tumor angiogenesis, improve tumor microenvironment, inhibit tumor growth, invasion and metastasis by acting on receptor tyrosine kinases such as DDR1 / 2, VEGFR 2 / 3 and PDGFR α / β. Icp-033 is a kind of innovative drug with global independent intellectual property rights. It plans to treat liver cancer, renal cell cancer, colorectal cancer and other solid tumors with immunotherapy and other targeted drugs alone or in combination.

This text is a result of machine translation.